Cargando…

Clinical Benefit of Switching from Low-Dose to High-Dose Empagliflozin in Patients with Type 2 Diabetes

INTRODUCTION: Sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors ameliorate blood glucose levels in patients with type 2 diabetes mellitus (T2DM) by inhibiting the reabsorption of glucose from the kidneys, thus increasing urinary glucose excretion. Most SGLT2 inhibitors have been reported t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsumura, Takeshi, Makabe, Tomoko, Ueda, Seiko, Fujimoto, Yuki, Sadahiro, Kayo, Tsuruyama, Shiori, Ookubo, Yuma, Kondo, Tatsuya, Araki, Eiichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399319/ https://www.ncbi.nlm.nih.gov/pubmed/35840857 http://dx.doi.org/10.1007/s13300-022-01296-y

Ejemplares similares

Thiazolidinedione‐independent activation of peroxisome proliferator‐activated receptor γ is a potential target for diabetic macrovascular complications
por: Matsumura, Takeshi, et al.
Publicado: (2011)

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
por: Shimoda, Seiya, et al.
Publicado: (2013)

Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
por: Isono-Nakata, Rose, et al.
Publicado: (2018)

Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis
por: Calçada, Marta Brandão, et al.
Publicado: (2021)

Treatment Outcomes of Graded Dose of Empagliflozin in Type-2 Diabetes: A Real World Study
por: Dutta, Deep, et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2013)

Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review
por: Kedia, Rohit, et al.
Publicado: (2016)

Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis
por: Shi, Zepeng, et al.
Publicado: (2022)

The Role of Heat Shock Response in Insulin Resistance and Diabetes
por: Kondo, Tatsuya, et al.
Publicado: (2014)

Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition
por: Jun, Seungho, et al.
Publicado: (2019)

Impacts of the 2016 Kumamoto Earthquake on glycemic control in patients with diabetes
por: Kondo, Tatsuya, et al.
Publicado: (2018)

Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
por: Yang, Ai-Yu, et al.
Publicado: (2020)

A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes
por: Johnston, Curtis K., et al.
Publicado: (2021)

Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes
por: Deng, Xinru, et al.
Publicado: (2022)

Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes
por: Araki, Eiichi, et al.
Publicado: (2022)

Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy
por: Perkins, Bruce A., et al.
Publicado: (2020)

The clinical course and pathophysiological investigation of adolescent gestational diabetes insipidus: a case report
por: Kondo, Tatsuya, et al.
Publicado: (2018)

Platelet transfusions: trigger, dose, benefits, and risks
por: Blumberg, Neil, et al.
Publicado: (2010)

Increasing the dose of acute rehabilitation: is there a benefit?
por: Parker, Ann M, et al.
Publicado: (2013)

Double dose alglucosidase-alpha doubles benefit?
por: Finsterer, Josef, et al.
Publicado: (2018)

Sunshine and the cardiovascular benefits – a dose of sunshine!
por: Straughan, John L
Publicado: (2010)

Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination
por: Fuwa, Masahiro, et al.
Publicado: (2016)

Association between circulating leukocyte subtype counts and carotid intima-media thickness in Japanese subjects with type 2 diabetes
por: Matsumura, Takeshi, et al.
Publicado: (2013)

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
por: Pellicori, Pierpaolo, et al.
Publicado: (2020)

Correction to: “Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes”
Publicado: (2022)

Angular dependence correction of MatriXX and its application to composite dose verification
por: Shimohigashi, Yoshinobu, et al.
Publicado: (2012)

Effect of topical agents on skin surface dose in volumetric modulated arc therapy for head and neck cancer
por: Ueda, Hikari, et al.
Publicado: (2023)

Updates of incretin‐related drugs for the treatment of type 2 diabetes
por: Araki, Hirotaka, et al.
Publicado: (2022)

Neuoroprotective efficacies by KUS121, a VCP modulator, on animal models of retinal degeneration
por: Hasegawa, Tomoko, et al.
Publicado: (2016)

Empagliflozin as add‐on to linagliptin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52‐week, randomized, placebo‐controlled trial
por: Kawamori, Ryuzo, et al.
Publicado: (2018)

Linagliptin as add‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, placebo‐controlled trial
por: Kaku, Kohei, et al.
Publicado: (2018)

RADIATION DOSE IN PAEDIATRIC COMPUTED TOMOGRAPHY: RISKS AND BENEFITS
por: Ogbole, G.I.
Publicado: (2010)

Health Benefits from Nature Experiences Depend on Dose
por: Shanahan, Danielle F., et al.
Publicado: (2016)

Benefits of prescribing low-dose digoxin in atrial fibrillation
por: Rosca, Ciprian Ilie, et al.
Publicado: (2021)

Molecular circuits, biological switches, and nonlinear dose-response relationships.
por: Andersen, Melvin E, et al.
Publicado: (2002)

Switching pattern and dose adjustment of antidepressants before and during pregnancy
por: Robiyanto, Robiyanto, et al.
Publicado: (2023)

Surface Engineering of Top7 to Facilitate Structure Determination
por: Ito, Yuki, et al.
Publicado: (2022)

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2021)

Empagliflozin Administration Can Decrease the Dose of Loop Diuretics and Prevent the Exacerbation of Renal Tubular Injury in Patients With Compensated Heart Failure Complicated by Diabetes
por: Shirakabe, Akihiro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v7871849qcm9euv93ufs4evc8p